Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mel Hayes
Mel Hayes is recorded as COO at Fulcrum Therapeutics, Inc. (FULC). Fulcrum Therapeutics, Inc. reported in an 8-K filed October 2, 2023 that Mel Hayes was terminated as chief operating officer (and principal operating officer), effective October 2, 2023. Fulcrum Therapeutics, Inc. reported in an 8-K filed August 11, 2022 that Mel Hayes was appointed chief operating officer, effective August 9, 2022. The proxy statement of Fulcrum Therapeutics, Inc. reports total compensation of $2,192,854 for Mel Hayes in fiscal 2023, including a base salary of $471,200.
“On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum's current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer.”
“On August 11, 2022, Fulcrum Therapeutics, Inc., or Fulcrum, announced that its board of directors promoted Mel Hayes, its current chief commercial officer, to the position of chief operating officer effective August 9, 2022, such date the Effective Date.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-08-09–present
-
Fulcrum Therapeutics, Inc. (FULC)
Proxy statement
Current -
2022-08-09–2023-10-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Fulcrum Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Alex C. Sapir CEO, Board Member
- Bryan Stuart CEO, COO, Board Member
- Robert J. Gould CEO
- Kate Haviland Chairman
- Mark Levin Chairman
- Alan A. Musso CFO
- Peter Thomson CFO
- Robert E. Gould CFO
- Alan Musso Chief Accounting Officer
- Gregory Tourangeau Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Fulcrum Therapeutics, Inc. (FULC) | Executive Vice President, Patient Affairs | $471,200 | $2,192,854 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.